Zura Bio (ZURA) Projected to Post Earnings on Thursday

Zura Bio (NASDAQ:ZURA) will likely be announcing its Q1 2025 earnings results before the market opens on Thursday, May 8th. Analysts expect the company to announce earnings of ($0.17) per share for the quarter.

Zura Bio (NASDAQ:ZURA) last issued its quarterly earnings data on Tuesday, March 25th. The company reported ($0.08) EPS for the quarter, beating the consensus estimate of ($0.17) by $0.09. The firm had revenue of $0.00 million for the quarter. On average, analysts expect Zura Bio to post $-1 EPS for the current fiscal year and $-1 EPS for the next fiscal year.

Zura Bio Price Performance

NASDAQ ZURA opened at $1.22 on Wednesday. Zura Bio has a 1 year low of $0.97 and a 1 year high of $6.35. The stock has a market capitalization of $83.42 million, a PE ratio of -2.30 and a beta of 0.05. The business’s 50-day moving average is $1.28 and its 200 day moving average is $2.17.

Institutional Inflows and Outflows

A hedge fund recently raised its stake in Zura Bio stock. Bank of America Corp DE raised its holdings in shares of Zura Bio Limited (NASDAQ:ZURA) by 31.9% in the fourth quarter, according to its most recent Form 13F filing with the SEC. The institutional investor owned 41,222 shares of the company’s stock after purchasing an additional 9,966 shares during the period. Bank of America Corp DE owned 0.06% of Zura Bio worth $103,000 as of its most recent SEC filing. 61.14% of the stock is owned by hedge funds and other institutional investors.

Wall Street Analysts Forecast Growth

Several research firms have recently issued reports on ZURA. Oppenheimer reissued an “outperform” rating and set a $19.00 target price (down from $20.00) on shares of Zura Bio in a research note on Wednesday, March 26th. Guggenheim restated a “buy” rating and issued a $15.00 price objective on shares of Zura Bio in a report on Wednesday, March 26th. HC Wainwright reaffirmed a “buy” rating on shares of Zura Bio in a research note on Thursday, April 3rd. Finally, Chardan Capital decreased their price target on shares of Zura Bio from $12.00 to $10.00 and set a “buy” rating for the company in a research note on Wednesday, March 26th. Seven analysts have rated the stock with a buy rating and one has issued a strong buy rating to the company’s stock. According to MarketBeat.com, the stock currently has a consensus rating of “Buy” and a consensus target price of $14.67.

About Zura Bio

Zura Bio Limited, a clinical-stage biotechnology company, focuses on developing novel medicines for immune and inflammatory disorders. It develops Tibulizumab, an IgG-scFv bispecific dual-antagonist antibody engineered by the fusion of ixekizumab and tabalumab that neutralizes IL-17A and BAFF, which is in Phase 2 clinical trial development; ZB-168, a monoclonal antibody that binds and neutralizes the IL-7 receptor chain that impact on diseases driven by IL7 and thymic stromal lymphopoietin immune pathways; and Torudokimab, a monoclonal antibody that neutralizes IL33, which is in Phase 2 clinical trial development.